The antidepressant fluvoxamine delivered clinically relevant reductions in long COVID fatigue, but the diabetes drug metformin didn't outdo placebo, according to the randomized REVIVE-TOGETHER trial.
Among 399 adults with long COVID, those receiving fluvoxamine had a significant reduction in fatigue as measured by the Fatigue Severity Scale (FSS) compared with placebo at day 60 (mean difference - 0.43, 95% credible interval [CrI] -0.80 to -0.07), with a 99% posterior probability of superiority, reported Jamie Forrest, PhD, MPH, of the University of British Columbia in Vancouver, and colleagues.
This effect was sustained at day 90 (mean difference -0.58, 95% CrI - 0.98 to -0.16), with a 99.7% probability of superiority.